Moleculin Biotech is trading 5.57% down in pre-market at $0.73 after investors reacted to a Nasdaq delisting determination disclosed on September 18, 2026.
- It failed Nasdaq’s $1.00 minimum bid-price requirement for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- The company plans to request a hearing, which would temporarily stay suspension or delisting actions.